Myriad Genetics
Offers hereditary cancer, tumor profiling, prenatal, and GeneSight pharmacogenomic tests.
$3.16
After-hours close+0.02 (+0.48%)
At close$3.15(−1.10%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 96.05%Insiders 7.12%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 94.45M · Float 87.86M · 93.0% free float
Institutions13F, as of Jun 30, 2026
200 holders · 90.72M shares · 44 new positions · 118 increased · 59 reduced · 50 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.89M | 11.53% | +2.00M | Aug 7, 2026 |
| Millennium Management LLC | 6.62M | 7.01% | −48.4K | Aug 14, 2026 |
| Vestal Point Capital, LP | 5.74M | 6.07% | +4.09M | Aug 14, 2026 |
| State Street Corp | 4.99M | 5.28% | +561.0K | Aug 7, 2026 |
| D. E. Shaw & Co., Inc. | 4.58M | 4.85% | +82.4K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 4.08M | 4.32% | +156.9K | Aug 13, 2026 |
| Acadian Asset Management LLC | 3.13M | 3.31% | +818.4K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 3.08M | 3.26% | +497.4K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.50% | 7.98M | 13G | Apr 7, 2026 ↗ |
| Vestal Point Capital, LP | 6.10% | 5.74M | 13G | Aug 14, 2026 ↗ |
| Integrated Core Strategies (US) LLC | 5.60% | 5.18M | 13G | Feb 11, 2026 ↗ |
| State Street Corporation | 5.30% | 4.99M | 13G | Aug 7, 2026 ↗ |
| Glenview Capital Management, LLC | 5.30% | 4.94M | 13G | Jan 13, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Samraat S. Raha | director, officer: President and CEO | 1.07M | 1.13% | Jun 12, 2026 |
| Paul J. Diaz | director, officer: President and CEO | 891.8K | 0.94% | Mar 25, 2025 |
| Mark Verratti | officer: Chief Operating Officer | 629.6K | 0.67% | Apr 15, 2026 |
| Brian J. Donnelly | officer: Chief Commerical Officer | 573.4K | 0.61% | Jun 12, 2026 |
| S. Louise Phanstiel | director | 341.7K | 0.36% | Jun 5, 2026 |
| Dale Muzzey | officer: Chief Scientific Officer | 326.3K | 0.35% | Apr 15, 2026 |
| Jennifer Lynne Fox | officer: Chief Legal Officer | 310.4K | 0.33% | Mar 16, 2026 |
| Benjamin Richard Wheeler | officer: Chief Financial Officer | 289.7K | 0.31% | Aug 17, 2026 |
| Shereen Solaiman | officer: Chief People Officer | 267.8K | 0.28% | Mar 16, 2026 |
| Raj Jampa | officer: Chief Technology Officer | 251.9K | 0.27% | Jun 2, 2026 |
33 people have not refiled in the last 18 months (3.38M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 8, 2026 | Rashmi Kumardirector | Sale | 15,000 | $4.46 | 171,889 |
| May 14, 2026 | Paul Bisarodirector | Purchase | 7,500 | $3.69 | 97,441 |
| Mar 9, 2026 | Samraat S. Rahadirector, officer: President and CEO | Purchase | 40,000 | $5.00 | 493,104 |
| Feb 25, 2026 | S. Louise Phanstieldirector | Purchase | 6,100 | $4.74 | 183,544 |
| Feb 26, 2026 | S. Louise Phanstieldirector | Purchase | 50,407 | $4.80 | 233,951 |
| Feb 27, 2026 | S. Louise Phanstieldirector | Purchase | 48,000 | $4.66 | 281,951 |
CongressHouse and Senate disclosures
Not reported.